Ipratropium Bromide and Albuterol Sulfate
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Ipratropium Bromide and Albuterol Sulfate
- Generic name
- IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE
- Manufacturer
- Nephron Pharmaceuticals Corporation
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- ae35ec1f-526a-49bf-8262-c50e40190d1f
- SPL ID
- 514ff8fb-abbb-c93c-e063-6394a90ac989
- Version
- 15
- Effective date
- 2026-05-08
- Source export date
- 2026-11-13
- Source partition
- 2
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/3b4204ed830f35b16ab24b2123672d7d93066eb0fd8af1cf09b223d0e4568221/drug-label-0002-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:31:26
| Harmonized routes |
|---|
| RESPIRATORY (INHALATION) |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 076749 | derived:openfda.application_number |
| application number | ANDA076749 | openfda.application_number | |
| brand name | Ipratropium Bromide and Albuterol Sulfate | openfda.brand_name | |
| generic name | IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE | openfda.generic_name | |
| manufacturer name | Nephron Pharmaceuticals Corporation | openfda.manufacturer_name | |
| ndc | package | 0487-0201-60 | openfda.package_ndc |
| ndc | package | 0487-0201-02 | openfda.package_ndc |
| ndc | package | 0487-0201-03 | openfda.package_ndc |
| ndc | package | 0487-0201-01 | openfda.package_ndc |
| ndc | product | 0487-0201 | openfda.product_ndc |
| ndc11 | package | 00487020103 | derived:openfda.package_ndc |
| ndc11 | package | 00487020101 | derived:openfda.package_ndc |
| ndc11 | package | 00487020160 | derived:openfda.package_ndc |
| ndc11 | package | 00487020102 | derived:openfda.package_ndc |
| rxcui | 1437702 | openfda.rxcui | |
| spl id | 514ff8fb-abbb-c93c-e063-6394a90ac989 | id | |
| spl set id | ae35ec1f-526a-49bf-8262-c50e40190d1f | set_id | |
| unii | J697UZ2A9J | openfda.unii | |
| unii | 021SEF3731 | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
IMMEDIATE HYPERSENSITIVITY REACTIONS Immediate hypersensitivity reactions to albuterol and/or ipratropium bromide may occur after the administration of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution as demonstrated by rare cases of urticaria, angioedema, rash, pruritis, oropharyngeal edema, bronchospasm, and anaphylaxis.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Adverse reaction information concerning Ipratropium Bromide and Albuterol Sulfate Inhalation Solution was derived from the 12-week controlled clinical trial. Additional adverse reactions reported in more than 1% of patients treated with Ipratropium Bromide and Albuterol Sulfate Inhalation Solution included constipation and voice alterations. In the clinical trial, there was a 0.3% incidence of possible allergic-type reactions, including skin rash, pruritis, and urticaria. Additional information derived from the published literature on the use of albuterol sulfate and ipratropium bromide singly or in combination includes precipitation or worsening of narrow-angle glaucoma, acute eye pain, blurred vision, mydriasis, paradoxical bronchospasm, wheezing, exacerbation of COPD symptoms, drowsiness, aching, flushing, upper respiratory tract infection, palpitations, taste perversion, elevated heart rate, sinusitis, back pain, sore throat and metabolic acidosis. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. b5387e98-figure-04
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.